Abstract
Patients with metastatic breast cancer with chemotherapy-sensitive disease, good performance status, and few sites of metastatic disease are the best candidates for high-dose chemotherapy and autologous stem cell reinfusion. Even in this selected subset of patients with metastatic breast cancer, at best 30% to 40% will maintain a complete remission beyond 2 years. In the high-risk adjuvant setting, high-dose chemotherapy appears efficacious; however, results from ongoing randomized prospective trials will not be available for several years.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 631-645 |
| Number of pages | 15 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1993 |
ASJC Scopus subject areas
- Hematology
- Oncology
